Plasma Cell Dyscrasia clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, not yet accepting patients
The complex logistics and unique toxicities of chimeric antigen receptor T-cell (CAR-T) therapy require intensive patient education and careful monitoring. The Companion for CAR-T (CC) web app may be able to assist with patient education and preparation, communication between patients and their multidisciplinary teams, and home-based toxicity monitoring.
San Francisco, California
Our lead scientists for Plasma Cell Dyscrasia research studies include Rahul Banerjee, MD.